Evidence map›Paper›PMID 38779031›Full record

ArticleHeliyon2024

Epigenetic-related gene-based prognostic model construction and validation in prostate adenocarcinoma.

Youyou Li, Chao Li, Longxiang Wu, Jiaren Li, Yu Gan, Shuo Tan, Lei Zhou, Wei Xiong, Liang Zhou, Cheng Li and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Youyou LiDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Chao LiDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Longxiang WuDepartment of Urology, The Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jiaren LiDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Yu GanDepartment of Urology, The Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Shuo TanDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Lei ZhouDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Wei XiongDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Liang ZhouDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Cheng LiDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Jiahao LiuDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Dingwen LiuDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Yichuan WangDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Yunlong FuDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Kun YaoDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Long WangDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate adenocarcinoma (PRAD), driven by both genetic and epigenetic factors, is a common malignancy that affects men worldwide. We aimed to identify and characterize differentially expressed epigenetic-related genes (ERGs) in PRAD and investigate their potential roles in disease progression and prognosis. We used PRAD samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to identify prognosis-associated ERGs. Thirteen ERGs with two distinct expression profiles were identified through consensus clustering. Gene set variation analysis highlighted differences in pathway activities, particularly in the Hedgehog and Notch pathways. Higher epigenetic scores correlated with favorable prognosis and improved immunotherapeutic response. Experimental validation underscored the importance of CBX3 and KAT2A, suggesting their pivotal roles in PRAD. This study provides crucial insights into the epigenetic scoring approach and presents a promising prognostic tool, with CBX3 and KAT2A as key players. These findings pave the way for targeted and personalized interventions for the treatment of PRAD.

Indexed as

BioinformaticsEpigeneticsImmunotherapyPrognostic modelProstate adenocarcinoma

Identifiers

PMID38779031
PMCPMC11109796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.